Guided Therapeutics (GTHP) Non-Current Debt (2013 - 2025)

Guided Therapeutics has disclosed Non-Current Debt across 12 years of filings, most recently posting $23000.0 for Q4 2025.

• Non-Current Debt for Q4 2025 came in at $23000.0, down 51.06% year-over-year; the trailing twelve-month figure through Dec 2025 was $23000.0 (down 51.06% YoY), and the FY2025 annual result was $23000.0, down 51.06% from the prior year.
• Non-Current Debt came in at $23000.0 for Q4 2025 at Guided Therapeutics, down from $29000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $586000.0 in Q3 2021 to a low of $6000.0 in Q1 2021.
• The 4-year median for Non-Current Debt is $50000.0 (2024), against an average of $159500.0.
• Across the five-year window, Non-Current Debt sank 98.96% in 2021 and soared 9366.67% in 2022, its largest moves.
• Guided Therapeutics' Non-Current Debt stood at $22000.0 in 2021, then jumped by 277.27% to $83000.0 in 2022, then sank by 43.37% to $47000.0 in 2024, then slumped by 51.06% to $23000.0 in 2025.
• The last three Non-Current Debt figures came in at $23000.0 (Q4 2025), $29000.0 (Q3 2025), and $35000.0 (Q2 2025), per Business Quant data.